Neonatal diabetes secondary to mutations in potassium-channel subunits is a rare disease but constitutes a paradigm for personalized genetics-based medicine, as replacing the historical treatment with insulin injections with oral sulfonylurea (SU) therapy has been proven beneficial. SU receptors are widely expressed in the brain, and we therefore evaluated potential effects of SU on neurodevelopmental parameters, which are known to be unresponsive to insulin.
activating mutation in the coding sequences of the KCNJ11 or ABCC8 gene (3), both of which encode the Kir6.2 subunit and SUR1 subunit, respectively, of the K ATP channel. In b-cells, this channel induces membrane depolarization, thereby triggering insulin granule exocytosis (4, 5) . Sulfonylureas (SUs), which are widely used to treat type 2 diabetes, bind specifically to SUR1, closing the K ATP channel via an ATP-independent mechanism and therefore increasing the release of insulin. We and others have shown that SUs are effective when used instead of subcutaneous insulin in children and adults with Kir6.2-or SUR1-activating mutations (5, 6) . SU therapy provided excellent metabolic control without the hypoglycemic episodes commonly seen with insulin.
Studies have established that ;20% of patients with mutations in K ATP genes have abnormalities of the standard neurological evaluation ranging from mild to severe developmental delay. The concomitant presence of treatmentresistant epilepsy and muscle weakness is known as developmental delay, epilepsy and neonatal diabetes (DEND) syndrome (3, 7) ; intermediate DEND is a less severe phenotype without epilepsy. However, we recently reported that appropriate testing methods detected developmental impairments in .70% of patients with K ATP gene mutations (3) . These impairments adversely affect academic performance, social functioning, and quality of life. They might be improved by SU therapy, since K ATP channels are found in many tissues, including the brain and muscle (8, 9) , and play a role in membrane polarization and cell functions. Anecdotal case reports support this possibility (2, 7, 10) .
We hypothesized that a successful switch from insulin to SU in patients with neonatal diabetes owing to K ATP channel mutations would improve developmental parameters. We conducted a prospective single-center cohort study of patients successfully switched from insulin to SU therapy. In-depth neurodevelopmental assessments were performed just before the switch and then 12-18 months later.
RESEARCH DESIGN AND METHODS
The appropriate ethics committee (CPP Ile-de-France 1) approved the study. SUs are not licensed for use in children in France, and we therefore obtained approval for SU therapy in our patients from both the CPPÎle-de-France 1 and the French Healthcare Agency (ANSM). Written informed consent was obtained from the parents or patients before study inclusion.
Study Population
We prospectively included 19 patients seen at the Pediatric Endocrinology and Diabetology Unit of Hôpital Universitaire Necker Enfants Malades Paris between 10 July 2006 and 4 February 2009 who had neonatal diabetes owing to documented mutations in the coding sequence of KCNJ11 or ABCC8. Exclusion criteria were known hypersensitivity to SUs, severe renal failure (creatinine clearance ,30 mL/min), severe hepatic failure (prothrombin rate ,70%), porphyria, imidazole therapy, pregnancy, or no coverage by the statutory health care insurance system. Of the 19 patients, 18 completed the study and 1 was withdrawn when the parents decided to decline the switch from insulin to SU. The switch from insulin to oral SU (glibenclamide) was performed as previously described (5, 6) . Patients were evaluated 2, 6, 12, and 18 months after inclusion.
French Neuromotor Functions in Children Battery
The French Neuromotor Functions in Children (NP-MOT) battery (11) was performed at baseline and then after 12 months to evaluate development via qualitative (movements) and quantitative (speeds) assessments of muscle tone, gross motor control, laterality, praxis, gnosopraxis (12) , digital and manual dexterity, body spatial integration, rhythmic tasks, and an auditory attentional task (12, 13 Overall test-retest reliability of the NP-MOT has been reported to range from 70 to 98% (11) , and correlation coefficients with the Lincoln-Oseretsky motor development scale (similar to the BruininksOseretsky Test of Motor Proficiency [14] for upper-limb coordination, balance, and bilateral coordination subtests) were 0.72 and 0.84 in two studies (15, 16 [19] ), visualspatial structuring (manual copy followed by visual-spatial memory of a complex geometric figure [20] ), and the Development Test of Visual-Motor Integration (21) , which involves manually copying 24 geometric drawings of progressively increasing complexity. Visual-spatial attention was assessed using a bell-crossing test (22) similar to that developed by Gauthier, Dehaut, and Joanette. Mental executive function was evaluated using the Porteus Maze Test (23) and the Tower of London test (24). In addition, the patients performed visual perception (visual gnosis) tasks (recognizing tangled lines and naming animals seen in outline from the rear) (25) and a language screening battery (22) . Hyperactivity was defined using the DSM criteria. Children's behavior was observed by the same examiner at inclusion and 12 months after the switch. The examiner recorded the symptoms characterizing the disorder: inattentiveness, impulsivity, and overactivity. Parents were administered an interview covering a broad range of child behaviors. As a part of this interview, parents were asked about the presence/absence of hyperactivity symptoms.
Electrophysiological Assessment of Visual Function
Each patient underwent an electroretinogram and visual evoked potential recordings, as recommended by the International Society for Clinical Electrophysiology of Vision (26, 27) , at baseline and then 6 months later. Flash visual evoked potentials were recorded in younger patients (monocular, patient no. 10, or binocular if patching an eye was not possible, patient nos. 1, 6, 18, 15, 7, 12, and 14) and pattern reversal visual evoked potentials in older patients (100% contrast; reversal at 1.0 Hz; 60', 30', or 15' squares, patient nos. 4, 9, 11, 17, 3, 5, and 16) . No recordings were performed in patient nos. 2 and 13.
Electrophysiological Muscle and Nerve Testing
Electrophysiological testing was performed at baseline and then after 6 and 12 months in children older than 6 years of age and carrying a KCNJ11 mutation (as SUR1 expressed by ABCC8 is Table 2 -Assessment using NP-MOT at baseline and then 12 months after starting SU therapy in 8 patients younger than 4 years of age at baseline (patient nos. 1-8)
Abnormal at baseline
Abnormal after 12 months of SU Median score difference (range)
Tone
Passive tone 6 (75) 1 (12.5) 21 (21 to 0), P = 0.06** Improved n = 5
Stable n = 1 Still normal n = 2 Standing tone (score , 8) 6 (75) 0 (0%) 2 (026), P = 0.03** Improved n = 6 Still normal n = 2 Motricity Gross motor skills (delay .2 months) 3 (37.5) 1 (12.5) 2 (27 to 3), P = 0.19** Improved n = 3 Degradation n = 1 Still normal n = 4 Fine motor skills (delay .2 months) 5 (62.5) 2 (25) 1 (25.5 to 3.5), P = 0.07** Improved n = 3
Stable n = 2 Still normal n = 3 Attention Attention 3 (37.5) 1 (12.5)
Data are n (%) unless otherwise indicated. The value presented in the parentheses in the last column is the range of score differences in values for the patients. The lowest score is 21 and 0 is the highest. *McNemar xnot expressed in the muscle). A standardized protocol ensuring reproducible and painless electrophysiological testing of skeletal muscle excitability was used (28) . Briefly, compound muscle action potentials were recorded from the right and left abductor digiti minimi muscles after supramaximal electrical stimulation of the ulnar nerves at the wrists. Recordings were repeated before and after voluntary contraction of the recorded muscle. If the response changed after exercise, care was taken to check that the electrode positions were unchanged and that nerve stimulation remained supramaximal. 10 (100) 10 (100) Improved n = 1 0 (0-4), P = 0.50 Stable n = 9 Visual-spatial construction 9 (90) 9 (90) Improved n = 3 15 (0-50), P = 0.06 Stable n = 6 Still normal n = 1 Data are n (%) unless otherwise indicated. CA, chronological age; M0, baseline (just before starting SU therapy); M12, 12 months after starting SU therapy; PA, performance age. *Paired Wilcoxon test on continuous scores.
Two provocative tests were performed. The first was a repeated short exercise test at room temperature on the left hand (three maximal, isometric, 10-s abductor digiti minimi contractions separated by 50-s rest periods during which compound muscle action potentials were recorded every 5-10 s). Then, a long exercise test was performed at room temperature on the right hand (maximal, isometric, 5-min abductor digiti minimi contraction followed by compound muscle action potential recording every 5 min for 40 min). Compound muscle action potential amplitude, total duration, and total area were expressed as percentages of pre-exercise values.
Needle electrode recordings were obtained from five muscles (deltoid, extensor digitorum communis, first interosseus dorsalis, vastus medialis, and tibialis anterior) to look for myotonic discharges or evidence of myopathy. Finally, motor conduction of the ulnar and peroneal nerves and sensory conduction of the right and left superficial peroneal nerves were measured. Amplitude, latency, and conduction velocity of the electrophysiological signals were compared with normal values for the laboratory. 
H-MRS.

Pharmacological Assessment
Plasma glibenclamide concentrations were determined after standard liquidliquid extraction by liquid chromatographyion-trap tandem mass spectrometry as previously described (29) . 
RESULTS
Study Population
We studied 18 patients aged 5 months to 18 years; eight were younger than 4 years old. Metabolic control improved after the switch to glibenclamide therapy, and no patients experienced hypoglycemia. One patient had a remission allowing glibenclamide discontinuation after the 12-month evaluation (Table 1) .
Median glibenclamide dosage was 0.37 mg/kg/day (range 0-1.4) at month 18. Median plasma glibenclamide concentration was 50 mg/L (interquartile range 21.5-118), and median area under the time curve over 24 h was 1,335 mg z L/h (511-2,122).
Neurological Evaluation
Neurological impairments were found in a single patient (patient no. 17) and consisted of a global pyramidal syndrome with spasticity and mild walking disability, mild mental retardation, and seizures (DEND). The baseline electroencephalogram was Patients were tested using the Brunet-Lézine test at baseline and then 12 months after starting SU therapy. CA, chronological age; M0, baseline (just before starting SU therapy); M12, 12 months after starting SU therapy; PA, performance age; pts, patients. *One patient (patient 2) was not evaluated at the 12-month time point. **Paired Wilcoxon test on continuous scores. 
Motor Skills
As previously reported, NP-MOT showed developmental coordination disorder, attention deficit, or both in 17 of the 18 patients. Impairments in the planning or programming of movements were combined with hypotonia in 15 patients. Tables 2 and 3 report the impairments at baseline and the improvements after 12 months of SU therapy. Individual results are reported in Supplementary Tables 1 and 2 . These abnormalities improved markedly after 12 months of SU therapy. Thus, in young children, tone was closer to the normal for chronological age and attention disorders had resolved, with normalization of gross motor skills in all children but one and of fine motor skills in three children. In children older than 4 years of age, tone, visual attention, and laterality improved. These changes benefited gesture conception and realization by ameliorating sensory integration and central gesture planning. Thus, body spatial integration, gesture imitation, and visual-spatial integration were improved. Motor skills were the area with the greatest improvements during SU therapy.
Language
Language disorders or delay were found in six patients at inclusion. They were not improved after 12 months of therapy (Tables 4 and 5 ).
Sociability and Hyperactivity
Social skills were altered at inclusion in four children younger than 4 years of age. Two children presented with hyperactivity. Sociability was not significantly improved after 12 months of SU, whereas hyperactivity had resolved (Tables 1, 4 , and 5).
Development and Intelligence Scores
Development was moderately delayed in five children younger than 2.5 years of age. In older children, intelligence scores were altered. Total IQ score was decreased in four patients. None of these items improved significantly with SU therapy in either age-group (Tables 4 and 5 ).
Electrophysiological Assessment of Visual Function
Ophthalmoscopy, ocular anatomy, and electroretinography were normal in all patients. Visual evoked potentials were delayed in all but one of the eight youngest patients. Pattern reversal potentials were normal in all but one patient. After 5 months of SU therapy, follow-up examinations in five of eight patients showed normalization of visual evoked potentials in two patients.
Electrophysiological Muscle and Nerve Testing
The 10 patients who underwent electrophysiological testing had normal motor and sensory nerve conduction studies at baseline. The short and long exercise tests induced minor and nonsignificant changes in compound muscle action potential amplitude and area, suggesting absence of membrane excitability impairments (Fig. 1) .
Cerebral MRI
MRI was performed in 17 patients (one family refused MRI) and was abnormal in 12 (71%). Nonspecific findings included cerebellar venous angioma (n = 1), posterior periventricular white matter abnormalities (n = 4), and Virshow-Robin space dilation (n = 2). Eight patients had multiple punctate white matter hyperintensities on T2 and FLAIR sequences (Fig.  2B) , and two had hyperintensities in the nucleus raphe pontis (Fig. 2) . 1 H-MRS was consistently normal.
CONCLUSIONS
We conducted a systematic prospective evaluation of potential effects of SU therapy in patients with neonatal diabetes owing to K ATP channel mutations. In keeping with our previous work (3), severe neurological deficiencies were uncommon, whereas developmental coordination disorders, language impairments, and attention deficiencies were often detected when appropriate tests were used. Electrophysiological testing showed no evidence of the membrane excitability alterations reported in muscle channelopathies, suggesting a neurological origin to the hypotonia and motor impairments. The detection by cerebral MRI of white matter abnormalities in most patients supports a central neurological origin to the motor and developmental impairments. The electrophysiological assessment of visual function also argued for a central origin, as it showed alterations in central sensory integration. Motor abnormalities were noticeably improved after 12 months of SU therapy. In the younger patients, hypotonia and attention deficits were greatly improved or corrected, contributing to ameliorations in motor skills. In patients older than 4 years, tone, laterality, and visual functions showed the greatest improvements, and these contributed to measurable improvements in gesture conception and realization. Neither intelligence scores nor language impairments improved within the study period, whereas hyperactivity was corrected in the affected patients. SU plasma concentrations and area under the curve values were within the therapeutic range for adults (29) . Our findings support an effect of SU therapy on the central nervous system in patients with permanent or transient neonatal diabetes owing to KCNJ11 or ABCC8 mutations. This effect seems to target specific brain regions, as the greatest improvements were for cerebellar functions (tone, gesture imitation, and body spatial integration) and thalamic functions (tone, laterality, gesture imitation, and visual-spatial construction) involved in various steps of gesture conception and realization such as sensory integration and motor planning.
Several anecdotal case reports are consistent with our findings. A 23-month-old boy with a KCNJ11 mutation and marked developmental delay experienced substantial improvements in motor function and attention with no change in intelligence scores (30). SU therapy started at 12 years of age in a boy who had a KCNJ11 mutation induced marked improvements in mental and motor function, with an increase in the Mental Developmental Index from 29 to 39 months within 6 months (7). Attention and gross and fine motor skills improved. MRI showed white matter abnormalities similar to those in our population. In a 6-year-old girl with a KCNJ11 mutation, improvements in muscle tone, motor function, attention, and hyperactivity were apparent 7 months after switching to SU therapy (10) . A study of 19 children with KCNJ11 mutations focused on visuomotor performance, which correlated negatively with age at SU initiation; however, the patients were tested on a single occasion: after SU initiation (31) . In our study, SU therapy in the younger patients was associated with a direct neuronal effect, improving visual conduction and thereby sensory integration and visual attention. This effect probably participated in the motor gains by improving the integration of visual sensory signals.
The neurological and developmental abnormalities seen in patients with neonatal diabetes owing to KCNJ11 or ABCC8 mutations are the result of the genetic abnormality and not of diabetes. Furthermore, they are ascribable to the effects of the mutation in central nervous system cells rather than to muscle excitability impairments. The Kir6.2 and SUR1 subunits are widely expressed in all brain regions in rodents and probably form the K ATP channel pores in most neurons (8, 9) . K ATP channels are also found in muscle. However, we found no evidence of abnormalities in muscle responses to exercise in patients with mutations in the KCNJ11 gene that encodes the Kir6.2 subunit. In contrast, exerciseinduced decreases in the amplitude and area of compound muscle action potentials have been reported in patients with periodic paralysis due to mutations in sodium (SCN4A), calcium (CACNA1S), or Kir2.1 potassium (KCNJ2) channel genes (28, 32) . Thus, the muscle disorders in patients with KCNJ11 mutations do not seem ascribable to changes in muscle membrane excitability. Furthermore, they are ascribable to the effects of the mutation in central nervous system cells rather than to muscle excitability impairments (33) . None of our patients had a history of recurrent severe hypoglycemia. The MRI changes in our patients differ from those reported in children with type 1 diabetes (34,35). These last two facts support the direct effect on the central nervous system rather than an indirect effect due to improved metabolic control.
Limitations of our study include the small sample size, although we included most of the patients in France who had neonatal diabetes owing to potassiumchannel subunit mutations and had not yet been switched to SU. A control group would have been ethically unacceptable. The short study period was sufficient to see substantial coordination disorders improvement allowing complex tasks such as handwriting to be better performed. If we found no major changes in language, intelligence, or sociability, these functions might improve with time, as this short study was sufficient to correct hyperactivity signs, or, alternatively, SUs may fail to target the brain regions involved. A major strength of our study is the use of a standardized normative neurodevelopmental test battery validated in normal French children and performed by a single examiner. This battery allowed us to obtain accurate information about SU effects on developmental parameters.
SUs have already been suggested as a neuroprotective drug after strokes (36, 37) . Our findings strongly suggest that SU therapy improves neurodevelopmental parameters in patients with neonatal diabetes owing to potassium-channel subunit mutations and acts via a central mechanism. The greater improvements in younger patients indicate a need for establishing the diagnosis early to allow prompt initiation of SU therapy. Further follow-up of our patients will provide information about the kinetics of SU effects on neurodevelopmental parameters.
